If you are on the lookout for some new portfolio additions, then it could be worth hearing what analysts at Morgans are saying about the ASX shares named below, courtesy of The Bull .

Are they bullish, bearish, or something in between? Let's find out.

Morgans has given its verdict on this sleep treatment company this week.

The broker has concerns that the ASX share could be negatively impacted by cost pressure arising from the conflict in the Middle East.

As a result, it has put a hold rating on ResMed shares. It said:

This global company develops, makes, distributes and markets medical devices for diagnosing, treating and managing respiratory conditions, including sleep disordered breathing. RMD management recently flagged emerging cost pressures from Middle East tensions. It was a response to higher fuel prices and early signs of component inflation .

However, RMD's fundamentals remain sound, with consistent execution, strong cash generation and structural growth tailwinds from expanding diagnosis and supplies. In our view, investors should continue holding the stock.